BR112014009717A8 - derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson. - Google Patents

derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson.

Info

Publication number
BR112014009717A8
BR112014009717A8 BR112014009717A BR112014009717A BR112014009717A8 BR 112014009717 A8 BR112014009717 A8 BR 112014009717A8 BR 112014009717 A BR112014009717 A BR 112014009717A BR 112014009717 A BR112014009717 A BR 112014009717A BR 112014009717 A8 BR112014009717 A8 BR 112014009717A8
Authority
BR
Brazil
Prior art keywords
parkinson
disease
treatment
pyrid
phenyl
Prior art date
Application number
BR112014009717A
Other languages
English (en)
Other versions
BR112014009717B1 (pt
BR112014009717A2 (pt
Inventor
Estrada Anthony
K Chan Bryan
Baker-Glenn Charles
Chambers Mark
Kevin Sweeney Zachary
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of BR112014009717A2 publication Critical patent/BR112014009717A2/pt
Publication of BR112014009717A8 publication Critical patent/BR112014009717A8/pt
Publication of BR112014009717B1 publication Critical patent/BR112014009717B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

resumo patente de invenção: "derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson". a presente invenção refere-se a compostos da fórmula (i), ou sais farmaceuticamente aceitáveis destes, em que m, n, x, r1, r2, r3, r4 e r5 são como definidos aqui. também divulgados são métodos de fabricar os compostos e usar os compostos para o tratamento de doenças associadas com o receptor de lrrk2, tal como doença de parkinson. (i) 21088169v1
BR112014009717-8A 2011-11-29 2012-11-28 Derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica BR112014009717B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564755P 2011-11-29 2011-11-29
US61/564,755 2011-11-29
PCT/EP2012/073768 WO2013079495A1 (en) 2011-11-29 2012-11-28 2-(phenyl or pyrid-3-yl) aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease

Publications (3)

Publication Number Publication Date
BR112014009717A2 BR112014009717A2 (pt) 2017-04-18
BR112014009717A8 true BR112014009717A8 (pt) 2018-01-16
BR112014009717B1 BR112014009717B1 (pt) 2022-06-14

Family

ID=47263348

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009717-8A BR112014009717B1 (pt) 2011-11-29 2012-11-28 Derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica

Country Status (20)

Country Link
US (1) US8791130B2 (pt)
EP (2) EP3121174A1 (pt)
JP (1) JP6180426B2 (pt)
KR (1) KR102025451B1 (pt)
CN (2) CN106243090A (pt)
BR (1) BR112014009717B1 (pt)
CA (1) CA2850705C (pt)
CY (1) CY1118135T1 (pt)
DK (1) DK2785711T3 (pt)
ES (1) ES2592802T3 (pt)
HR (1) HRP20161396T1 (pt)
HU (1) HUE030694T2 (pt)
LT (1) LT2785711T (pt)
MX (1) MX348920B (pt)
PL (1) PL2785711T3 (pt)
PT (1) PT2785711T (pt)
RS (1) RS55370B1 (pt)
RU (1) RU2647849C2 (pt)
SI (1) SI2785711T1 (pt)
WO (1) WO2013079495A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5986094B2 (ja) * 2010-11-10 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体
BR112014011219B1 (pt) * 2011-11-29 2022-08-23 Genentech, Inc. Derivados de aminopirimidina, seus usos, e composição farmacêutica
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
US20140228384A1 (en) * 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
EP2844658B1 (en) * 2012-05-03 2019-03-20 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
WO2015069752A1 (en) * 2013-11-05 2015-05-14 The Regents Of The University Of California Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
US10058559B2 (en) 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
TR201908151T4 (tr) * 2014-10-08 2019-06-21 Ucb Biopharma Sprl İzoindolin türevleri.
WO2016130920A2 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
CN114315819A (zh) 2016-06-16 2022-04-12 戴纳立制药公司 作为用于治疗神经退化性病症的lrrk2抑制剂的嘧啶-2-基氨基-1h-吡唑
MX2020005332A (es) 2017-11-21 2021-01-08 Denali Therapeutics Inc Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion.
MA51339A (fr) 2017-12-20 2020-10-28 Denali Therapeutics Inc Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
PL3966207T3 (pl) 2019-05-10 2024-03-04 Deciphera Pharmaceuticals, Llc Fenyloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
PE20220592A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos
KR20220024605A (ko) 2019-06-17 2022-03-03 데시페라 파마슈티칼스, 엘엘씨. 아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트
CN113121528B (zh) * 2020-01-15 2022-12-13 中国科学院上海药物研究所 多靶点抑制作用化合物、组合物、功能分子及其应用
JP2023524935A (ja) 2020-03-23 2023-06-14 ファニン ファーマシューティカル カンパニー リミテッド 新規なピリミジン誘導体及びこれを含む神経退行性疾患及び癌の予防又は治療用組成物
KR102342803B1 (ko) 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2024097394A1 (en) 2022-11-03 2024-05-10 Denali Therapeutics Inc. Solid and co-crystal forms of a pyrimidine triazole compound
WO2024112746A1 (en) 2022-11-22 2024-05-30 Denali Therapeutics Inc. Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096888A1 (de) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
JP4460292B2 (ja) * 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
CA2502970A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2007149789A2 (en) 2006-06-22 2007-12-27 Applera Corporation Conversion of target specific amplification to universal sequencing
WO2009103652A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
US20100056524A1 (en) * 2008-04-02 2010-03-04 Mciver Edward Giles Compound
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
EP2483254B1 (en) 2009-09-29 2014-08-13 Glaxo Group Limited Novel compounds
CN103038230B (zh) * 2010-06-04 2016-05-25 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
JP5986094B2 (ja) * 2010-11-10 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体
BR112014011850B1 (pt) * 2011-11-29 2022-01-11 Genentech, Inc Derivados de aminopirimidina, seus usos, e composição farmacêutica
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
BR112014011219B1 (pt) * 2011-11-29 2022-08-23 Genentech, Inc. Derivados de aminopirimidina, seus usos, e composição farmacêutica

Also Published As

Publication number Publication date
JP6180426B2 (ja) 2017-08-16
DK2785711T3 (en) 2016-09-05
PL2785711T3 (pl) 2017-01-31
LT2785711T (lt) 2016-10-25
BR112014009717B1 (pt) 2022-06-14
US8791130B2 (en) 2014-07-29
CN103958503B (zh) 2016-09-28
WO2013079495A1 (en) 2013-06-06
JP2014533737A (ja) 2014-12-15
EP2785711B1 (en) 2016-08-03
EP2785711A1 (en) 2014-10-08
KR102025451B1 (ko) 2019-09-25
RU2014124639A (ru) 2016-01-27
CN106243090A (zh) 2016-12-21
HRP20161396T1 (hr) 2016-12-02
EP3121174A1 (en) 2017-01-25
US20130158057A1 (en) 2013-06-20
CA2850705C (en) 2020-03-10
RU2647849C2 (ru) 2018-03-21
KR20140094649A (ko) 2014-07-30
CY1118135T1 (el) 2017-06-28
BR112014009717A2 (pt) 2017-04-18
HUE030694T2 (en) 2017-06-28
RS55370B1 (sr) 2017-03-31
MX348920B (es) 2017-07-04
SI2785711T1 (sl) 2016-12-30
MX2014006210A (es) 2014-08-08
CA2850705A1 (en) 2013-06-06
PT2785711T (pt) 2016-09-30
ES2592802T3 (es) 2016-12-01
CN103958503A (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
BR112014009717A8 (pt) derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson.
BR112013011600A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2
BR112014011219A2 (pt) derivados de aminopirimidina como moduladores de lrrk2
BR112012030820A2 (pt) "derivados de aminopirimidina como moduladores de lrrk2"
BR112014011850A2 (pt) derivados de aminopirimidina como moduladores de lrrk2
BR112014012217A2 (pt) derivados de 2-fenilaminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson
BR112014027117A2 (pt) derivados de pirazol aminopirimidina como moduladores de lrrk2 para uso no tratamento de doença de parkinson
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
MX349470B (es) Compuesto heterocíclico y su uso.
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
BRPI0615613A2 (pt) diaminopirimidinas como moduladores de p2x3 e p3x2/3
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
BR112014005468A2 (pt) derivados de aminopiridina para uso como moduladores de atividade quinase
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MX2013005833A (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
BR112013026807A2 (pt) derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato
BR112012006387A2 (pt) aminas de triazol fundidas como moduladores de p2x7
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
UY33191A (es) Derivados de pirazina
BR112014000499A2 (pt) compostos de quinolona de aminometila
BR112013027982A2 (pt) derivados de isoindolinona

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GENENTECH, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/11/2012, OBSERVADAS AS CONDICOES LEGAIS